Today, Bedrocan produces five plant varieties for patient use. Each product is standardised according to pharmaceutical standards with a defined active ingredient composition. This reproducible chemical profile allows doctors to monitor dosage and condition progress like they would with any other treatment.
At Bedrocan we consider scientific research a vital tool to make medicinal cannabis an approved medicine. That’s why we support clinical trials worldwide and offer our services and experience to medicinal cannabis research projects.
Bedrocan products are used by the pharmaceutical industry. Standardised Active Pharmaceutical Ingredients (API) of pharmaceutical quality, in various formats, meet the needs of large and small drug developers.
On June 9 and 10, the Central European Cannabis Forum (CECF) hosts ‘Medical Cannabis in Poland and CEE’; the largest virtual conference on medical cannabis in the CEE region’. Bedrocan CEO Tjalling Erkelens will join the opening panel on June 9.
On May 6, MJBizDaily issued a new edition of ”Medical Cannabis in Europe”. Co-author Alfredo Pascual shares some conclusions. “The European market growth that many companies often project in their investors’ decks isn’t necessarily based in reality.”